TRAVERE THERAPEUTICS, INC. Increase (Decrease) in Other Operating Liabilities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Increase (Decrease) in Other Operating Liabilities of $4.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $2.95M, a 261.15% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $1.94M, a 173.62% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$589.00K, a 179.92% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was -$10.64M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for fiscal 2025 was -$9.70M, a 271.80% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for fiscal 2024 was $5.65M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for fiscal 2023 was -$418.00K.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in other operating liabilities for fiscal 2022 was -$1.61M, a 243.28% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.89M 10-Q · filed 2026-08-04 | $4.30M derived: sum of 3 quarters · filed 2026-08-04 | -$6.34M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.94M 10-Q · filed 2026-05-04 | $1.35M derived: sum of 2 quarters · filed 2026-05-04 | -$9.29M derived: sum of 3 quarters · filed 2026-05-04 | -$8.47M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$11.22M derived: sum of 2 quarters · filed 2026-02-19 | -$10.41M derived: sum of 3 quarters · filed 2026-08-04 | -$9.70M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | -$10.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$9.82M derived: sum of 2 quarters · filed 2026-08-04 | -$9.11M 10-Q · filed 2025-10-30 | -$8.37M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $816.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.52M 10-Q · filed 2026-08-04 | $2.26M derived: sum of 3 quarters · filed 2026-08-04 | $2.01M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $709.00K 10-Q · filed 2026-05-04 | $1.45M derived: sum of 2 quarters · filed 2026-05-04 | $1.20M derived: sum of 3 quarters · filed 2026-05-04 | -$1.68M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $737.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $489.00K derived: sum of 2 quarters · filed 2026-02-19 | -$2.39M derived: sum of 3 quarters · filed 2026-02-19 | $5.65M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | -$248.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$3.13M derived: sum of 2 quarters · filed 2025-10-30 | $4.91M 10-Q · filed 2025-10-30 | $5.71M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | -$2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.16M 10-Q · filed 2025-08-06 | $5.96M derived: sum of 3 quarters · filed 2026-02-19 | $5.71M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $8.04M 10-Q · filed 2025-05-01 | $8.84M derived: sum of 2 quarters · filed 2026-02-19 | $8.60M derived: sum of 3 quarters · filed 2026-02-19 | $7.86M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $799.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $557.00K derived: sum of 2 quarters · filed 2026-02-19 | -$180.00K derived: sum of 3 quarters · filed 2026-02-19 | -$418.00K 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | -$242.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$979.00K derived: sum of 2 quarters · filed 2024-10-31 | -$1.22M 10-Q · filed 2024-10-31 | -$479.00K 10-Q · filed 2023-11-07 | -$707.00K derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-06-30 | -$737.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$975.00K 10-Q · filed 2024-08-01 | -$483.00K 10-Q · filed 2023-08-03 | -$465.00K derived: sum of 3 quarters · filed 2025-02-21 | -$457.00K derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-03-31 | -$238.00K 10-Q · filed 2024-05-06 | $272.00K derived: sum of 2 quarters · filed 2025-02-21 | $280.00K derived: sum of 3 quarters · filed 2025-02-21 | $42.00K derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $518.00K derived: sum of 2 quarters · filed 2025-02-21 | $280.00K derived: sum of 3 quarters · filed 2025-02-21 | -$1.61M 10-K · filed 2025-02-21 | -$1.72M 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$230.00K derived: sum of 2 quarters · filed 2023-11-07 | -$2.12M 10-Q · filed 2023-11-07 | -$759.00K derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | -$238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.13M 10-Q · filed 2023-08-03 | -$767.00K derived: sum of 3 quarters · filed 2024-02-20 | -$551.00K derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | -$1.89M 10-Q · filed 2023-05-04 | -$1.80M 10-Q · filed 2022-05-05 | -$529.00K derived: sum of 2 quarters · filed 2024-02-20 | -$313.00K derived: sum of 3 quarters · filed 2024-02-20 | -$726.00K derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2021-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.58M derived: sum of 2 quarters · filed 2024-02-20 | $1.16M derived: sum of 3 quarters · filed 2024-02-20 | $1.12M 10-K · filed 2024-02-20 | $1.24M 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$197.00K derived: sum of 2 quarters · filed 2022-10-27 | -$237.00K 10-Q · filed 2022-10-27 | -$18.93M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | -$413.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$453.00K 10-Q · filed 2022-08-04 | -$19.14M derived: sum of 3 quarters · filed 2023-02-23 | -$651.00K derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | -$40.00K 10-Q · filed 2022-05-05 | $23.00K 10-Q · filed 2021-05-06 | -$18.73M derived: sum of 2 quarters · filed 2023-02-23 | -$238.00K derived: sum of 3 quarters · filed 2023-02-23 | $7.08M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | -$18.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$198.00K derived: sum of 2 quarters · filed 2023-02-23 | $7.13M derived: sum of 3 quarters · filed 2023-02-23 | -$394.00K 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $18.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $25.82M derived: sum of 2 quarters · filed 2021-10-29 | $18.30M 10-Q · filed 2021-10-29 | |||||
| 2020-06-30 | $7.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$196.00K 10-Q · filed 2021-07-29 | ||||||
| 2020-03-31 | -$7.52M 10-Q · filed 2021-05-06 | |||||||
| 2019-09-30 | -$417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$3.11M derived: sum of 2 quarters · filed 2020-11-05 | $6.78M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $7.20M 10-Q · filed 2020-07-31 | ||||||
| 2019-03-31 | $9.89M 10-Q · filed 2020-05-11 | |||||||
| 2018-09-30 | $609.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $883.00K derived: sum of 2 quarters · filed 2019-10-30 | $3.09M 10-Q · filed 2019-10-30 | |||||
| 2018-06-30 | $274.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.48M 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | $2.21M 10-Q · filed 2019-05-07 | |||||||
| 2017-09-30 | $2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $2.71M derived: sum of 2 quarters · filed 2018-11-01 | $2.56M 10-Q · filed 2018-11-01 | |||||
| 2017-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | -$45.00K 10-Q · filed 2018-08-03 | ||||||
| 2017-03-31 | -$146.00K 10-Q · filed 2018-07-06 | |||||||
| 2016-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.88M 10-Q · filed 2017-11-07 | ||||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |